K+S Again Rejects – Unchanged – Potash Bid

German potash and salt producer K+S has rejected a renewed attempt by Potash Corporation of Saskatchewan to take over the company. Attached to the letter, the company said, was a proposal for a Business Combination Agreement which it said “addresses the interests of workers and local communities but offers no reliability.”

Pointing out that the offer remained unchanged from the previous approach, Norbert Steiner, CEO of K+S, said the management and supervisory boards “are still convinced that the proposed price of €41 Euro does not at all reflect the fundamental value of K+S.”

“This is true for our existing business but in particular for the value contribution of our Legacy Project in Canada. For this reason alone, also the new proposal of PotashCorp is not in the best interest of the company.”

Steiner reiterated that the commitments proposed by PotashCorp do not provide reliability. “They are foiled by far-reaching restrictions in essential parts and are not effectively enforceable.”

From the perspective of the boards, he said, “the concern remains unchanged that the transaction proposed by PotashCorp puts jobs at risk and that sites and raw material production in Germany might not be maintained.”

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.